|
2022
|
P/S
|
Pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatmen... |
|
2021
|
Invention
|
Process for the preparation of purine derivatives exhibiting cdk inhibitory activity.
The presen... |
|
|
Invention
|
Process for the preparation of purine derivatives exhibiting cdk inhibitory activity. The present... |
|
2020
|
Invention
|
Dosing regimen. The present invention provides a method of treating acute myeloid leukemia (AML) ... |
|
|
Invention
|
Process for the preparation of a pyrimidino-diazepine derivative.
In one aspect, the invention r... |
|
|
Invention
|
Crystalline forms of pyrimidino diazepine derivative.
The present invention relates to new cryst... |
|
|
Invention
|
Crystalline forms of pyrimidino diazepine derivative. The present invention relates to new crysta... |
|
|
Invention
|
Process for the preparation of a pyrimidino-diazepine derivative. In one aspect, the invention re... |
|
2019
|
Invention
|
Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia... |
|
2018
|
Invention
|
Dosing regimen.
The invention relates to a method of treating AML in a subject having a white bl... |
|
|
Invention
|
Dosing regimen. A first aspect of the invention relates to a method of treating AML in a subject,... |
|
|
P/S
|
Pharmaceutical substances and preparations for the treatment
of cancer, haematological disorders... |
|
|
P/S
|
Pharmaceutical substances and preparations for the treatment of cancer, haematological disorders;... |
|
|
Invention
|
Process for preparing purine derivatives. 9 is other than H. Further aspects of the invention rel... |
|
|
Invention
|
Process for preparing purine derivatives. The present invention relates to a process for preparin... |
|
2017
|
Invention
|
Dosing regimen for sapacitabin and seliciclib. A first aspect of the invention relates to a metho... |
|
2015
|
Invention
|
Pyrimidine derivatives as protein kinase inhibitors. The present invention relates to pyrimidine ... |
|
2014
|
Invention
|
Crystalline forms of a purine derivative. The present invention relates to new crystalline forms ... |
|
|
P/S
|
Pharmaceutical preparations and biopharmaceuticals for the treatment of cancer. |
|
2013
|
Invention
|
Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabin... |
|
|
Invention
|
Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine an... |
|
|
Invention
|
Pyrimidine derivatives as protein kinase inhibitors. 8 are each independently H or alkyl. Further... |
|
|
Invention
|
Dosage regimen for sapacitabine and seliciclib. A first aspect of the invention relates to a meth... |
|
|
Invention
|
Treatment of proliferative diseases with pyrimidodiazepinones.
A first aspect of the invention r... |
|
|
Invention
|
Treatment of proliferative diseases with pyrimidodiazepinones. A first aspect of the invention re... |
|
2012
|
Invention
|
Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) ... |
|
|
Invention
|
Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases. The ... |
|
2011
|
Invention
|
Method for selecting a cancer therapy.
The present invention provides a method for determining w... |
|
2009
|
Invention
|
Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in t... |
|
|
Invention
|
Trisubstituted purine derivatives. The present invention relates to compounds of formula (I)
6 i... |
|
|
P/S
|
Pharmaceutical preparations and biopharmaceuticals for the
treatment of cancer. |
|
|
Invention
|
Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and p... |
|
|
Invention
|
Preparation of intermediates useful in the synthesis of 2′-cyano-2′-deoxy-n4-palmi-toyl-1-β-d-ara... |
|
|
Invention
|
Intermediate and processes involved in the preparation of 2 ' -cyano-2 ' -de0xy-n4-palmit0yl-1-be... |
|
|
Invention
|
Preparation of intermediates useful in the synthesis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-a... |
|
|
Invention
|
Preparation of intermediates useful in the syntheis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-ar... |
|
2007
|
Invention
|
Combination comprising cndac (2′-cyano-2′-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) ... |
|
2006
|
Invention
|
Combination of roscovitine and a hdca inhibitor to treat proliferative diseases.
A first aspect ... |
|
|
Invention
|
Antiproliferative combination comprising cyc-682 and a cytotoxic agent.
A first aspect of the in... |
|
|
Invention
|
Pyrimidin-4-yl-3, 4-dihydro-2h-pyrrolo [1,2a] pyrazin-1-one compounds. 3, alkyl and alkoxy, where... |
|
|
Invention
|
4-(1h-indol-3-yl)-pyrimidin-2-ylamine derivatives and their use in therapy.
The present inventio... |
|
2001
|
P/S
|
Chemical preparations for pharmaceutical and medical purposes; pharmaceutical preparations and su... |
|
1997
|
P/S
|
[ pharmaceutical preparations for the treatment of degenerative diseases ] [ medical services; ] ... |
